Scholars Central

ArticlePublished 2015

Implementation of a Robust Pharmacovigilance Method for Filgrastim Non-Innovator Products in Cancer Patients in Routine Clinical Practice Complying With Mexican Regulations for Biocomparables

Authors: Huerta-Sanchez Olivid Marisol, Aguilar-Ponce José Luis, Meneses-García Abelardo, Herrera-Gómez Ángel, Herrera-Hernández Ricardo, Monroy-Cruz María Teresa, Burgeño-Ferreira Juan Andrés, Castañeda-Hernández Gilberto, López-Gamboa Mireya

Journal of Pharmacovigilance

Volume 3 · Issue 4 · Pages 1–6

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Background and aim: Mexico, as other countries, has recently changed regulatory requirements for noninnovator biopharmaceuticals (biocomparables); a suitable pharmacovigilance program being now mandatory. Hence, our aim was to implement a robust pharmacovigilance method for filgrastim products of different brands used in routine clinical practice in Mexico. Method: Prospective, phase IV, non-interventional study performed at the Instituto Nacional de Cancerología (National Institute of Cancerology) of Mexico. All pharmacy dispensations of filgrastim products were reviewed and recorded during four months. Patients received a diary for voluntary notation of adverse drug reactions (ADR) every time they were dispensed filgrastim. Additionally, medical records were consulted and contrasted with patientgenerated information. ADR analysis was performed according to the Mexican official norm on pharmacovigilance NOM-220-SSA1-2012. Results: The procedure allowed to trace which filgrastim brand was administered to every patient. 373 patients received diaries. 214 patients returned diaries with information suitable for further analysis. Very common ADRs were musculoskeletal pain and headache. Common ADR were pain in extremities, asthenia, general body pain, nausea, pain in site of injection, vomit, paresthesia, abdominal discomfort, decreased appetite and diarrhoea. All ADRs were probably or possibly related to filgrastim and corresponded to previously reported ADRs. No new ADRs were detected. Conclusion: The used methodology was robust enough to identify and characterize ADRs for each filgrastim brand product directly from patient information. It thus allows performing pharmacovigilance studies for biopharmaceuticals, both innovator and non-innovator, guaranteeing traceability and complying with current Mexican regulations for biocomparables.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Pharmacovigilance
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Huerta-Sanchez Olivid Marisol”
  • BylineArticles whose byline prints “Aguilar-Ponce José Luis”
  • BylineArticles whose byline prints “Meneses-García Abelardo”
  • BylineArticles whose byline prints “Herrera-Gómez Ángel”
  • BylineArticles whose byline prints “Herrera-Hernández Ricardo”
  • BylineArticles whose byline prints “Monroy-Cruz María Teresa”
  • BylineArticles whose byline prints “Burgeño-Ferreira Juan Andrés”
  • BylineArticles whose byline prints “Castañeda-Hernández Gilberto”